dig sound guidanc
ow multi-year growth narr
solid guidanc set doubl digit earn growth outlook guidanc
oper revenu growth view reassur lend
doubl digit ep growth invest year lay foundat growth
beyond anticip invest new product
innov includ mab vaccin diagnost strategi integr
offer support trio launch also discuss recent
inflect year diagnost integr system abaxi three recent
refer lab network etho phoenix znlab refer recent note
anticip stage eu launch simparica trio uk spain itali month
continu expect increment revenu net cannib
estim could product refer outlook
continu expect us approv trio end-march anticip price around
expect around gm benefit trio off-set fx confirm
manag indic trio gm benefit would continu rise time see trio
core driver growth next year see geograph expans
ahead expect growth outlook intact report result ahead
expect revenue/adj ep consensu
companion anim segment grew y/i driven intern segment
y/i derm portfolio contribut strong growth expect livestock
segment y/i oper total revenu growth
y/i gm shi consensu manag expect swine
cattl return growth refer recent note asf impact
stay ow rais pt revis estim tweak revenu
higher ep lower higher tax rate stay ow valu
price target rais use price-to-earnings multipl previou risk
delay trio launch asf continu impact china econom slowdown
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
idc link barclay live interact chart
overweight ow driven
new launch companion anim health
greater thrust toward biolog drug
unmet need chronic diseas pet also
expect continu effici alloc
capit done past value-ad
strong global growth faster anticip margin
expans earlier launch symparica trio valu
weak integr abaxi delay launch
symparica trio greater anticip competit
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
report revenu consensu adj ep
consensu companion anim segment grew y/i oper
driven intern segment growth y/i oper livestock
segment y/i oper total revenu growth y/i
gross margin shi consensu
within us growth quarter companion anim grow
expect driven flagship dermatolog brand inorgan boost platinum
perform nutrit formula recent launc proheart also strong
perform us livestock growth continu led poultri previou
quarter beef dairi sector week
segment anoth strong quarter oper growth
companion anim deliv report oper basi livestock
led poultri recent launch
report result ahead
consensu driven continu
initi guidanc manag provid revenu guidanc
adjust ep oper revenu growth guidanc
net incom growth overal guidanc roughli in-lin
consensu higher end rang
consensu high end initi guidanc rang
valu rais use price-to-earnings multipl rais
risk thesi includ downsid fx headwind usd strength higher-than-
anticip gener threat global macro slowdown increas incid
asf upsid acceler global growth value-ad
valu month pt rais
asf implic anim health
growth see paw part ii stori continu etho acquisit
pe multiplehistor average multipl base per share barclay zoeti inc
balaji prasad md herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
